<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39366462</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-8541</ISSN><JournalIssue CitedMedium="Internet"><Volume>595</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of theoretical biology</Title><ISOAbbreviation>J Theor Biol</ISOAbbreviation></Journal><ArticleTitle>Exploring the treatment of SARS-CoV-2 with modified vesicular stomatitis virus.</ArticleTitle><Pagination><StartPage>111959</StartPage><MedlinePgn>111959</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtbi.2024.111959</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5193(24)00244-3</ELocationID><Abstract><AbstractText>SARS-CoV-2 caused a global pandemic and is now an endemic virus that will require continued antiviral and vaccine development. A possible new treatment modality was recently suggested that would use vesicular stomatitis virus (VSV) modified to express the ACE2 receptor. Since the modified VSV expresses the cell surface receptor that is used by the SARS-CoV-2 spike protein, the thought is that SARS-CoV-2 virions would bind to the modified VSV and thus be neutralized. Additionally, since SARS-CoV-2 infected cells also express the spike protein, the modified VSV could potentially infect these cells, allowing for its own replication, but also potentially interfering with replication of SARS-CoV-2. This idea has not yet been tested experimentally, but we can investigate the feasibility of this possible treatment theoretically. In this manuscript, we develop a mathematical model of this suggested treatment and explore conditions under which it might be effective. We find that treatment with modified VSV does little to change the SARS-CoV-2 time course except when the treatment is applied at the onset of the SARS-CoV-2 infection at very high doses. In this case, VSV reduces the peak SARS-CoV-2 viral load, but lengthens the duration of the SARS-CoV-2 infection. Thus, we find that modified VSV treatment is unlikely to be effective largely because it does not prevent infection of cells by SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright Â© 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Polavarapu</LastName><ForeName>Nishnath</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Physics &amp; Astronomy, Texas Christian University, Fort Worth, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doty</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Burnett School of Medicine at TCU, Fort Worth, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobrovolny</LastName><ForeName>Hana M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Physics &amp; Astronomy, Texas Christian University, Fort Worth, TX, United States. Electronic address: h.dobrovolny@tcu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Theor Biol</MedlineTA><NlmUniqueID>0376342</NlmUniqueID><ISSNLinking>0022-5193</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral treatment</Keyword><Keyword MajorTopicYN="N">Mathematical model</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vesicular stomatitis virus</Keyword><Keyword MajorTopicYN="N">Viral interference</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39366462</ArticleId><ArticleId IdType="doi">10.1016/j.jtbi.2024.111959</ArticleId><ArticleId IdType="pii">S0022-5193(24)00244-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>